Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation

J Cancer Res Clin Oncol. 2002 Jan;128(1):29-36. doi: 10.1007/s004320100270. Epub 2001 Nov 1.

Abstract

Purpose: High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has become an important treatment for solid tumors including lung cancer.

Methods: We measured IL-12 levels in patients with lung cancer undergoing autologous PBSCT in order to elucidate the role of IL-12 in immune response recovery following stem cell transplantation.

Results: Compared to IL-12 levels at 1 week after PBSCT for lung cancer patients, those at 3 weeks were significantly increased ( P<0.01). In contrast, serum IL-12 levels in malignant lymphoma patients did not change significantly. There were no significant differences in levels of other cytokines between 1 week and 3 weeks after transplantation in patients with lung cancer. The frequency of helper/inducer T cells was increased in peripheral blood 1 week after transplantation in both lung cancer and malignant lymphoma patients. There was a significant increase in activated T cell numbers following PBSCT. Furthermore, high levels of other activated T cells persisted in the post-PBSCT period in patients with lung cancer and the number of cytotoxic T cells significantly increased. Natural killer (NK) cell numbers also tended to increase, although that of malignant lymphoma was not significant. A strong correlation was observed between serum IL-12 levels and NK cell numbers and interferon-gamma levels in lung cancer not but in malignant lymphoma patients. The analysis of transfused PBSC showed that the numbers of granulocyte/macrophage colony-forming units were similar in lung cancer and malignant lymphoma patients. However, the number of CD34+ cells was significantly higher in lung cancer than in malignant lymphoma patients. All of the CD34+ subpopulations were lower in percentage in patients with lung cancer than in patients with malignant lymphoma. In particular, the CD34+ CD33- subpopulation was significantly lower in percentage in lung cancer patients.

Conclusion: Our findings suggest that PBSC in lung cancer are potent mediators of anticancer activity and that they might play an immunotherapeutic role against autologous malignant cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / blood
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Interferon-gamma / blood
  • Interleukin-12 / blood*
  • Interleukins / blood
  • Lung Neoplasms / blood
  • Lung Neoplasms / immunology*
  • Lung Neoplasms / therapy
  • Lymphoma / blood
  • Lymphoma / immunology*
  • Lymphoma / therapy
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Regression Analysis
  • T-Lymphocytes / immunology
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Helper-Inducer / immunology
  • Time Factors
  • Tissue and Organ Harvesting
  • Transplantation, Autologous*
  • Tumor Necrosis Factor-alpha / analysis
  • Vincristine / administration & dosage

Substances

  • Interleukins
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Interferon-gamma
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • EPOCH protocol